Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

78.01 +0.27 (+0.35%)
Streaming Delayed Price Updated: 1:21 PM EDT, May 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 792,143
Open 76.88
Bid (Size) 77.96 (100)
Ask (Size) 78.12 (400)
Prev. Close 77.74
Today's Range 76.62 - 79.67
52wk Range 13.42 - 80.27
Shares Outstanding 105,736,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗
Arrowhead (ARWR) Q2 2026 Earnings Transcript 
Via The Motley Fool
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Soars 70% After Hours on REDEMPLO Launch Momentum and Strong Q2 Earnings Beat ↗
Via Chartmill

Performance

YTD
+15.1%
+15.1%
1 Month
+22.3%
+22.3%
3 Month
+24.5%
+24.5%
6 Month
+95.8%
+95.8%
1 Year
+458.4%
+458.4%

More News

Read More
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Presents a High-Growth, Technical Breakout Opportunity ↗
Via Chartmill
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reports Profitable Quarter on Strong Drug Launch ↗
Via Chartmill
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Emerges as a Growth Stock with a Constructive Technical Setup ↗
Via Chartmill
News headline image
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Sarepta's RNA Renaissance: 35% Surge as siRNA Breakthrough Silences Skeptics
Via MarketMinute
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
Via MarketMinute
News headline image
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
Via Investor Brand Network
Topics Intellectual Property
News headline image
Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
From BioMedWire
Via GlobeNewswire
News headline image
The Great Rotation: How the 'One Big Beautiful Bill Act' is Igniting a Small-Cap Renaissance
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Arrowhead (ARWR) Q1 2026 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Ciena’s AI-Driven Return: Networking Giant to Join S&P 500 Benchmark
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire
News headline image
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
From Arrowhead Pharmaceuticals, Inc.
Via Business Wire

Frequently Asked Questions

Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?
Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market
What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?
The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 78.01
When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 05/12/26 01:21 PM ET
What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 8.25B
How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?
Arrowhead Pharmaceuticals, Inc. - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.